Menkes Disease
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Sentynl TherapeuticsCA - Solana Beach
2 programsLong Term Follow-UpN/A1 trial
copper histidinateN/A1 trial
Active Trials
NCT04074512Approved For Marketing
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Cyprium TherapeuticsCopper Histidine
Sentynl TherapeuticsLong Term Follow-Up
Clinical Trials (3)
Total enrollment: 143 patients across 3 trials
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Start: Feb 2009Est. completion: Aug 202093 patients
Phase 3Completed
Copper Histidinate Treatment for Menkes Disease
N/AApproved For Marketing
Long Term Follow-up on Menkes Disease Patients
Start: Dec 2019Est. completion: Aug 202650 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.